HemoCath pioneers advancements at the crossroads of Medtech and Digital Health, aiming to enhance care for individuals with heart failure (HF). The versatile and scalable HemoCath™ AI Platform enables proactive AI-data-driven management of patients with acute HF from diagnosis to treatment and monitoring for all hospital heart procedures. The user-friendly integrated Platform includes the HemoCath™ PA catheter securely connected to the Luc™ AI Cloud to continuously measure and monitor PAP & CVP, the leading indicators of heart congestion, allowing early targeted therapy. The vital health information remains easily available to the managing clinician, supporting optimal dosing of guideline-directed medical therapy (GDMT) across the entire spectrum of HF. Several clinical trials provide clinical evidence of a significant improvement in cardiac care and reduction in hospital stay with PAP-guided HF management. Learn more at www.hemocath.com